| Ytd | -61.86% | |
| 1y | -23.73% |
| Open | 4.50 | Prev Close | 4.32 | Low | 4.50 | High | 4.64 | Mkt Cap | 14.46M |
| Vol | 3.60K | Avg Vol | 75.15K | EPS | -11.84 | P/E | -0.38 | Forward P/E | -1.30 |
| Beta | 1.20 | Short Ratio | 6.61 | Inst. Own | 59.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-03 | 50-d Avg | 5.03 | 200-d Avg | 7.89 | 1yr Est | 8.00 |
PASG News
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst cons
Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-
Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecu
Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Pass
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendatio
Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf7
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy
Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) a
Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both sm
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g
The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. Whi
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g
The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock.
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PB
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plas
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
On Monday, 89 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings
On Thursday, 930 stocks hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.